Drugmaker GSK has agreed to pay up to 1.15 billion US dollars (£950 million) for a US-based biopharmaceutical company which is developing rare cancer therapies. GSK said the acquisition of IDRx will ...

GSK has agreed to buy US biopharmaceutical business IDRx in a deal worth up to $1.15billion (£1billion). Under the agreement, GSK will pay $1billion upfront to acquire the Massachusetts-based firm, ...

Drugmaker GSK has agreed to pay up to 1.15 billion US dollars for a US-based biopharmaceutical company (GSK/PA) Drugmaker GSK has agreed to pay up to 1.15 billion US dollars (£950 million) for a ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...